Repros Therapeutics

Repros Therapeutics — Investor Presentation (May 2017)

16 slides from Repros Therapeutics's investor presentation, May 2, 2017

  1. Slide 1: Repros Therapeutics Corporate Presentation May 2017

    REPROS THERAPEUTICS CORPORATE PRESENTATION MAY 2017 Dedicated to Treating Male and Female Reproductive Disorders

  2. Slide 2: Safe Harbor

    SAFE HARBOR Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties

  3. Slide 3: Company Overview

    COMPANY OVERVIEW • Originally founded as Zonagen – an animal health company using technology from Baylor University • IPO 1993 • Key recent developments • Patrick Fourteau named as Chairman of the Board • Larry Dillaha, M.D. named President and CEO • Important patent issuance with coverage until 202

  4. Slide 4: Experienced Management Team

    EXPERIENCED MANAGEMENT TEAM • Larry Dillaha , M.D. – President and CEO (Feb 2017) • Sanofi, Sciele / Shionogi, Insys Therapeutics • History of clinical and regulatory success • Kathi Anderson, CPA – CFO • Joined Repros in 2002 • More than 15 years in biotech, life sciences • Joe Wernicke, M.D., Ph.D

  5. Slide 5: Proellex (Telapristone Acetate) for Uterine Fibroids and Endometriosis

    PROELLEX ® ( TELAPRISTONE ACETATE) FOR THE TREATMENT OF UTERINE FIBROIDS AND ENDOMETRIOSIS • Licensed from NIH, 1999 • Selective Progesterone Receptor Modulator (SPRM) • No selectivity for glucocorticoid receptor • Need for chronic intermittent dosing • Lead Indications: • Treatment of Uterine Fibro

  6. Slide 6: Selective Progesterone Receptor Modulator (SPRM)

    SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM) • Evolved from Progesterone Antagonists • Mifepristone • Limited use because of high affinity for glucocorticoid receptor over progesterone receptor • Recognizing need for more selective progesterone receptor activity, SPRMs developed • Mixed agonist

  7. Slide 7: Uterine Fibroids

    UTERINE FIBROIDS • Benign smooth muscle tumors of uterus (leiomyomas) • Most common tumor of female reproductive tract • 20 - 77% of women aged 35 - 55 • Quality of Life often impacted • Heavy menstrual bleeding • Discomfort and pain • Current Therapy • Medications • NSAIDS, OCPs, GnRH agonists, Pro

  8. Slide 8: Endometriosis

    ENDOMETRIOSIS • Endometrial tissue growing outside the uterus • Infertility – Pain, including pelvic pain • Dyspareunia • D ysmenorrhea • 11% of women aged 15 - 44 • 25 - 40% of all cases of infertility • 71 - 87% of women with chronic pelvic pain • 53% teenagers with dysmenorrhea • Impact on QoL •

  9. Slide 9: How Antiprogestins Like Proellex Work

    HOW ANTIPROGESTINS LIKE PROELLEX® WORK GnRH agonists and antagonists. These agents: • Block hypothalamus / pituitary axis • Shut down hormonal secretions • Add - back hormonal therapy O O OMe N OAc CH 3 H 3 C Proellex ® Hypothalamus Pituitary Endometrial & Uterine Tissue Antiprogestins • Selectively

  10. Slide 10: Proellex Effectiveness in Patients

    PROELLEX ® EFFECTIVENESS IN PATIENTS 10 AN EFFECTIVE DOSE OF PROELLEX ® STOPS MENSTRUATION IN MAJORITY OF WOMEN Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhe

  11. Slide 11: Broad Patent Position on Proellex

    BROAD PATENT POSITION ON PROELLEX ® • Off Drug Interval • Recent issuance of patent ‘074 – expires 2027 • R elates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex ® ) or Ulipristal Acetate, with an Off Drug Interval (ODI) for the treatmen

  12. Slide 12: Regulatory / Development History

    REGULATORY / DEVELOPMENT HISTORY 12 Full Clinical Hold 2009 Partial Clinical Hold Phase II studies FDA Meeting Await FDA Feedback • Study doses 12mg and lower • Submit protocols • Increased liver monitoring • 2 cases of Hy’s Law • Doses of 50mg and 25mg • 6mg and 12 mg • Uterine Fibroids • Endometri

  13. Slide 13: Expected Regulatory Path Forward for Proellex

    EXPECTED REGULATORY PATH FORWARD FOR PROELLEX ® • Repros has empaneled group of world class liver experts to review data and provide opinion • Reached agreement with division to accept additional information from Repros, including opinion from company’s liver experts, for submission to FDA internal

  14. Slide 14: Significant Market Opportunity and Investment in This Therapeutic Area

    SIGNIFICANT MARKET OPPORTUNITY AND INVESTMENT IN THIS THERAPEUTIC AREA • Ulipristal Acetate • Gedeon Richter product • Partnered with Allergan for US market • On market in EU • Esmya 5 mg for Tx of UF • Recently completed phase III • Venus II trial • Publicly stated intent to file NDA in 2H17 • $520

  15. Slide 15: Enclomiphene for the Treatment of Secondary Hypogonadism

    ENCLOMIPHENE FOR THE TREATMENT OF SECONDARY HYPOGONADISM • NDA submitted Jan 2015 • Complete response letter received Nov 2015 • EMA filing under review present in EU market • Opinion date is anticipated in 1Q18 • Actively seeking partnering opportunities ex US 15

  16. Slide 16: Repros: Next Steps and Milestones

    REPROS : NEXT STEPS AND MILESTONES • Continue discussions with FDA and obtain feedback to determine future clinical trial program for Proellex ® for Uterine Fibroids and Endometriosis • Submit Proellex ® trial design to FDA • EMA filing under review for Enclomiphene for secondary hypogonadism • New

Repros Therapeutics — Investor Presentation (May 2017) on 6ix